We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Korean Practice Patterns for Screening PCA(Prostate Cancer) (RESPECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01371513
Recruitment Status : Completed
First Posted : June 10, 2011
Last Update Posted : May 22, 2017
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
This is to investigate Korean urologist's practice patterns for screening prostate cancer according to PSA level.

Condition or disease Intervention/treatment
Neoplasms, Prostate Prostate Cancer Benign Prostatic Hyperplasia Other: continuous screening

Detailed Description:
This is to investigate Korean urologist's practice patterns for screening prostate cancer according to PSA level.

Study Type : Observational
Actual Enrollment : 1 participants
Observational Model: Other
Time Perspective: Retrospective
Official Title: Korean's Practice Patterns for Screening PCA(Prostate Cancer) According to PSA(Prostate-specific Antigen) Level
Study Start Date : May 2010
Primary Completion Date : June 2011
Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
PSA level
more than 2.5ng/ml
Other: continuous screening
practice patterns for screening prostate cancer



Primary Outcome Measures :
  1. Number of subjects with prostate biopsy [ Time Frame: 1year ]

Secondary Outcome Measures :
  1. Number of subjects with prostate cancer [ Time Frame: 1year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Subjects with PSA more than 2.5ng/ml in 2008 from urology department of clinic and general hospital
Criteria

Inclusion Criteria:

  • Male with PSA more than 2.5ng/ml from 1 Jan 2008 to 31 Dec 2008

Exclusion Criteria:

  • Age less than 40 at PSA screening
  • History of drug use which can affect level of PSA within 6months before PSA screening
  • Subject who participate any other clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01371513


Locations
Korea, Republic of
GSK Investigational Site
Seoul, Korea, Republic of, 135-720
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01371513     History of Changes
Other Study ID Numbers: 113951
First Posted: June 10, 2011    Key Record Dates
Last Update Posted: May 22, 2017
Last Verified: May 2017

Keywords provided by GlaxoSmithKline:
Serum prostate specific antigen

Additional relevant MeSH terms:
Prostatic Neoplasms
Hyperplasia
Prostatic Hyperplasia
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Pathologic Processes